Merck & Co., Inc. Deferred Income Tax Expense (Benefit) in USD from Q1 2010 to Q1 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.
Summary
Merck & Co., Inc. quarterly/annual Deferred Income Tax Expense (Benefit) history and growth rate from Q1 2010 to Q1 2025.
  • Merck & Co., Inc. Deferred Income Tax Expense (Benefit) for the quarter ending March 31, 2025 was -$186M, a 265% decline year-over-year.
  • Merck & Co., Inc. annual Deferred Income Tax Expense (Benefit) for 2024 was -$1.25B, a 34.2% increase from 2023.
  • Merck & Co., Inc. annual Deferred Income Tax Expense (Benefit) for 2023 was -$1.9B, a 21.1% decline from 2022.
  • Merck & Co., Inc. annual Deferred Income Tax Expense (Benefit) for 2022 was -$1.57B, a 939% decline from 2021.
Deferred Income Tax Expense (Benefit), Quarterly (USD)
Deferred Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Deferred Income Tax Expense (Benefit), Annual (USD)
Deferred Income Tax Expense (Benefit), YoY Annual Growth (%)

Merck & Co., Inc. Quarterly Deferred Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2025 -$186M -$135M -265% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-02
Q1 2024 -$51M +$226M +81.6% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-02
Q1 2023 -$277M +$61M +18% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-03
Q1 2022 -$338M -$356M -1978% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-05
Q1 2021 $18M -$64M -78% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q1 2020 $82M -$112M -57.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-05
Q1 2019 $194M +$224M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q1 2018 -$30M +$24M +44.4% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q1 2017 -$54M +$16M +22.9% Jan 1, 2017 Mar 31, 2017 10-Q 2018-05-08
Q1 2016 -$70M +$109M +60.9% Jan 1, 2016 Mar 31, 2016 10-Q 2017-05-09
Q1 2015 -$179M +$125M +41.1% Jan 1, 2015 Mar 31, 2015 10-Q 2016-05-09
Q1 2014 -$304M -$233M -328% Jan 1, 2014 Mar 31, 2014 10-Q 2015-05-07
Q1 2013 -$71M -$30M -73.2% Jan 1, 2013 Mar 31, 2013 10-Q 2014-05-08
Q1 2012 -$41M +$173M +80.8% Jan 1, 2012 Mar 31, 2012 10-Q 2013-05-09
Q1 2011 -$214M -$366M -241% Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-08
Q1 2010 $152M Jan 1, 2010 Mar 31, 2010 10-Q 2011-05-09

Merck & Co., Inc. Annual Deferred Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$1.25B +$650M +34.2% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-25
2023 -$1.9B -$331M -21.1% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-25
2022 -$1.57B -$1.76B -939% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-25
2021 $187M +$753M Jan 1, 2021 Dec 31, 2021 10-K 2024-02-26
2020 -$566M -$6M -1.07% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-24
2019 -$560M -$51M -10% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-25
2018 -$509M +$2.11B +80.6% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-25
2017 -$2.62B -$1.1B -72.3% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-26
2016 -$1.52B -$757M -99.1% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-27
2015 -$764M +$1.84B +70.6% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-27
2014 -$2.6B -$2.27B -688% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-28
2013 -$330M -$999M -149% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-26
2012 $669M +$2.21B Jan 1, 2012 Dec 31, 2012 10-K 2015-02-27
2011 -$1.54B -$445M -40.8% Jan 1, 2011 Dec 31, 2011 10-K 2014-02-27
2010 -$1.09B Jan 1, 2010 Dec 31, 2010 10-K 2013-02-28
* An asterisk sign (*) next to the value indicates that the value is likely invalid.